Report contents
Industry landscape
Where the company competes: a global scanner market sold one hospital at a time
GE HealthCare sells the machines hospitals use to see inside the body, and increasingly the software, contrast media and radiopharmaceuticals that run through them. That puts it in medical imaging equipment and its attached consumables, a business that is global in manufacturing and research but national, sometimes local, in purchasing, reimbursement and service. The mix inside that arena is lopsided. In figures the company presented at the J.P. Morgan Healthcare Conference in January 2026, Imaging ran at $9.1 billion on a trailing 12-month basis, against $5.3 billion for Advanced Visualization Solutions, $3.1 billion for Patient Care Solutions and $2.8 billion for Pharmaceutical Diagnostics. Anything that moves Imaging moves the company.
The value chain is short on both ends. Upstream, GE HealthCare buys detectors, X-ray tubes, superconducting magnets, silicon and specialized components from a small supplier base, then designs and assembles scanners in its own plants. Downstream, it sells to radiology departments, hospital systems, private imaging and cardiology networks, and the group purchasing organizations that negotiate large fleet orders on their behalf. Capital budgets, not clinical preference alone, decide when a scanner is replaced, which is why refresh cycles matter as much as clinical performance. Regulatory clearance is the entry toll, and the company said at that January conference that it received 115 FDA authorizations for AI features in 2025 and showed more than 40 innovations at the Radiological Society of North America meeting.
The geographic boundary is national even though the product is sold worldwide. Each country sets its own reimbursement, its own device approval and its own expectations for service coverage, so a scanner installed in Ohio and one installed in Osaka compete in different arenas. The installed base then generates the recurring revenue: multi-year service contracts, contrast agents, and radiopharmaceutical doses tied to procedure volume. That attachment is where the growth story sits. Distribution partnerships the company cited for its Flyrcado cardiac imaging agent, including CDL Nuclear Technologies and the cardiology network CVAUSA, are attempts to reach procedure volume before rivals do.
Market structure: concentrated in nuclear imaging, crowded in CT
GlobalData, the industry research firm, sizes the two modalities where GE HealthCare's position is documented. Both are estimates from a third party, not audited figures.
| Market (GlobalData estimates) | 2025 size | 2030 estimate | GE HealthCare share |
|---|---|---|---|
| CT scanners | $8.6bn | $10.2bn | about 14.3% |
| PET and SPECT equipment | about $5bn | $7.2bn | about 34% |
Those two numbers describe very different competitive fields, and they cover only part of the portfolio. The CT figure equates to roughly $1.2 billion of revenue, well short of the $9.1 billion Imaging segment, which also includes MRI, ultrasound, X-ray and mammography. CT is a visible slice, not the whole position. On the PET and SPECT side, a 34% share of a $5 billion market implies about $1.7 billion, and GlobalData expects that market to reach $7.2 billion by 2030, with PET and hybrid systems doing most of the growing.
Naming rivals helps less than it should, because rival shares for these modalities are not publicly available. The credible competitors in CT and MRI are Siemens Healthineers, Philips, Canon Medical Systems, Fujifilm Healthcare and, increasingly in China, United Imaging Healthcare. In nuclear imaging the field is narrower, with Siemens Healthineers the main global rival and a smaller set of regional players. In radiopharmaceuticals, GE HealthCare competes with Cardinal Health, Curium, Lantheus and Jubilant DraxImage, a handful of firms with manufacturing and logistics networks that take years to replicate. Ultrasound is the most fragmented part of the business, with Samsung Medison, Mindray and Philips alongside GE HealthCare.
Barriers: medium in CT, higher where the dose is the product
The practical test for entry barriers is whether the leaders fit on one hand. In CT they do not: five or more credible vendors sell into the same hospital capital budgets, and GE HealthCare's estimated 14.3% share is consistent with a market where no one dictates price. That is the Greenwald market-share logic in one line: sustained share above roughly a third usually signals real barriers, and a leader in the mid-teens usually does not have them. In PET and SPECT, where the company's estimated share is 34%, the count of serious competitors shrinks, and the barriers rise with it.
The barrier in nuclear imaging is not the scanner alone. It is the combination of a cyclotron and radiopharmacy network, regulatory licenses for handling isotopes, and reimbursement codes for specific procedures. Flyrcado's economics illustrate the point: management has set an ambition of more than $500 million in revenue by 2028 and has argued that lifting PET's share of myocardial perfusion imaging from about 20% to 25% of procedures would open roughly a $1 billion opportunity in that indication. That is a forecast, not a result, and it depends on reimbursement and clinical guidelines moving as the company expects.
So the arena is really three arenas with different structures: competitive imaging hardware, a more concentrated nuclear franchise, and a fragmented ultrasound business. The evidence supports a moat in nuclear medicine and much less of one in CT. What would settle the CT question is rival share data that is not published; until consolidating share appears, the mid-teens position is best read as participation, not pricing power.
Competitive advantage
Does the company have a moat? Moderate, and only in nuclear medicine
GE HealthCare carries a Moderate competitive advantage. Its portfolio divides into two arenas with different economics. Imaging hardware pits several capable vendors against one another for the same hospital capital budgets. Nuclear medicine, and the contrast media and tracers attached to it, is a narrower field with heavier entry requirements. A single rating for the whole company hides that split.
Concentration, the first test, holds in only part of the portfolio. GlobalData estimates put GE HealthCare at about 14.3% of the CT scanner market and about 34% of PET and SPECT equipment. Those describe different competitive regimes. A mid-teens share in CT is consistent with a market where no supplier sets price, and Siemens Healthineers, Philips, Canon Medical Systems, Fujifilm Healthcare and United Imaging all sell to the same radiology departments. A 34% share in PET and SPECT, with Siemens Healthineers the main global rival, is closer to a duopoly. Consolidation in a slice of the business is not consolidation in the business.
Market position: one of several in CT, one of two in nuclear
Market share and rank: Moderate. GE HealthCare sits at the top of the modalities where its share is documented, but at very different levels. In CT it is one participant among several, and the GlobalData estimate of about 14.3% implies roughly $1.2 billion of scanner revenue in an $8.6 billion market. In PET and SPECT it is one of two global leaders; the estimates do not establish whether GE HealthCare or Siemens Healthineers is the larger. No published figure covers imaging as a whole, which is where about 71% of revenue sits, and CT, MRI, ultrasound, X-ray and mammography compete for overlapping hospital budgets.
Stability of market position: Moderate. Neither modality has a published five-year share series, and rival shares are not disclosed by modality, so the stability test cannot be run directly.
| GE HealthCare share (GlobalData estimates) | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| CT scanners | ~14.3% | ||||
| PET and SPECT equipment | ~34% |
Revenue is the available proxy. Sales went from $17.59 billion in FY2021 to $20.62 billion in FY2025, about 4% a year. That is growth in line with a market expanding at low single digits, which fits stable share without proving it. A share move of more than 5 percentage points over five years would argue against entry barriers; a move under 2 points would argue for them. Nothing published places GE HealthCare in either band, so the position reads as steady.
Profitability: about 10% on total capital, near 20% excluding goodwill
Returns on capital: Moderate. Reported ROE looks strong and is a poor guide. It was 14.3% in FY2021, 14.7% in FY2022, 37.6% in FY2023 and 25.6% in FY2024, per company filings. Leverage distorts the series: total liabilities equal about 71% of assets at the end of FY2025 against 35.8% at the end of FY2021, before the spin-off recapitalization, and at the end of FY2024 long-term debt of $7.45 billion sat against $8.45 billion of equity. FY2023 is distorted differently: net income of $3.10 billion exceeded operating income of $2.44 billion, which implies roughly $1.4 billion of non-operating income in the pretax result.
ROIC is the better measure. Computed as after-tax operating profit over total assets less current liabilities, it averaged about 10% a year from FY2021 through FY2025, in a range of 8.4% to 11.8%. Set goodwill aside, and it was $13.49 billion of the $36.91 billion of assets at the end of FY2025, and the same calculation averages about 24%. Both figures are estimates from reported statements, and which one applies decides the rating. If the relevant capital is what a rival would spend to replicate the business, returns sit comfortably above any plausible cost of capital. If it is what GE HealthCare actually paid, including the 2004 Amersham purchase that built the diagnostics franchise, returns have been roughly adequate. So far the evidence shows a modest excess return, not a wide one.
Margins are steady rather than expanding: gross margin was 39.1% in FY2022, 41.7% in FY2024 and 40.0% in FY2025, while net margin was 10.1% in both FY2024 and FY2025. A 40% gross margin on hospital hardware is the profile of a good industrial business. Siemens Healthineers and Philips report on different calendars and split their segments differently, so no clean like-for-like margin comparison is available. FY2025 revenue of $20.62 billion produced $2.76 billion of operating income, a 13.4% operating margin.
FY2025 operating cash flow was $1.99 billion against $2.08 billion of net income, with free cash flow of $1.51 billion. The first half of 2026 broke that pattern: operating cash flow of negative $0.23 billion against positive $0.34 billion a year earlier.
Overall rating: Moderate
Rated Moderate. Profitability falls short of the Fairly Strong bar, which caps the overall rating. A roughly 10% return on total invested capital is below what a protected franchise should earn, and the higher figure that excludes goodwill requires treating a 2004 acquisition premium as irrelevant. Market position is genuinely strong in nuclear medicine and ordinary in CT. The combination describes real advantages in part of the business and plain competition in the rest.
Where the advantage comes from and how long it can last: the installed base and the isotope supply chain
Two sources carry most of the weight: customer captivity built around an installed base of scanners, and the licensing, chemistry and logistics barrier in radiopharmaceuticals. Economy of scale reinforces both, but it does not stand on its own, because scale without captivity can be matched by a rival willing to buy share.
Customer captivity: Moderate, and renegotiated every ten years
Rating: Moderate. A scanner is a ten-year-plus capital asset, and the money follows the fleet. Once a hospital installs a GE HealthCare CT or MR, the service contract, contrast protocols, image-archiving software and technologist training all point in one direction, and each additional machine makes the next purchase easier to justify internally. Contrast media and tracers attach to the installed machine, so procedure volume converts into recurring revenue without a new sales fight every time.
The limits matter as much as the mechanism. The purchase decision is episodic and fully competitive: at replacement, Siemens Healthineers, Philips, Canon and United Imaging bid into the same budget line, and any accumulated captivity resets. Large health systems deliberately dual-source to preserve that competition, and service is contestable through in-house engineering teams and independent providers. Price sensitivity shows up in the results rather than in surveys. Gross margin has held near 40% and revenue has grown about 4% a year, which is not the pattern of a supplier that can raise price at will. Captivity here is worth more between purchases than at the point of purchase, and that ceiling limits how much it contributes.
Radiopharmaceuticals: Fairly Strong, in a slice that is still small
Rating: Fairly Strong. This is the narrowest part of the company and the best protected. Three requirements stack up before a rival can sell a single dose. The product needs regulatory clearance, and the company describes Flyrcado as the first FDA-approved F 18 agent for myocardial perfusion imaging, a first-mover position in a defined indication. The isotope needs a production and delivery network, because PET tracers decay within hours and cannot be warehoused or shipped long distances, so coverage has to be built site by site. The procedure also needs a reimbursement code before hospitals will pay for it.
An entrant that clears all three still faces the economics of route density: a radiopharmacy network pays only if enough scans run through each site. GE HealthCare has been buying that density through its Japanese radiopharmacy joint venture and an agreed U.S. PET-tracer distribution network, and it has signed distribution partners including CDL Nuclear Technologies and CVAUSA to reach cardiology practices. The same logic supports the equipment side, where the estimated 34% share of PET and SPECT gives the company an installed base into which its own tracers can be sold. The constraint is size. Pharmaceutical Diagnostics was about 14% of FY2025 revenue. Management's target of more than $500 million in Flyrcado revenue by 2028 is a forecast that depends on PET's share of myocardial perfusion imaging rising from roughly 20% to 25% of procedures, and the evidence so far shows approvals and partnerships rather than revenue.
Scale: Moderate, because it is spread across too many modalities
Rating: Moderate. The fixed costs are real. Manufacturing plants, a worldwide service engineer network, regulatory and quality systems, research spending and a global sales force all have to be carried whether or not a given quarter is busy. A large installed base spreads service and quality overhead across more machines, which is why recurring service carries better economics than equipment sales, and hospitals favor vendors with coverage in every region they operate in.
The weakness is relative share in the largest hardware modality. Scale protects a supplier when it comes with captivity and when it is concentrated against rivals. GE HealthCare's 54,000 employees are spread across CT, MR, ultrasound, X-ray, mammography and patient monitoring, and in CT, where unit volumes are highest, its estimated share is in the mid-teens. A rival does not need to match GE HealthCare's total size to compete in one modality. Where the company does concentrate, in nuclear imaging, scale and regulatory barriers work together rather than separately.
Substitutes: the hardware franchise is the exposed part
A hospital working up chest pain can use a nuclear scan on GE equipment with a GE tracer, or a CT-based alternative. The direction of substitution matters. A shift from SPECT toward PET helps the combined position, because GE HealthCare's PET share and its tracer franchise are both stronger than its CT share. A shift away from nuclear imaging toward CT would not.
Good-enough hardware is the more concrete threat. Refurbished scanners and third-party service cap what a hospital will pay for new equipment, and lower-cost Chinese scanners from United Imaging and Mindray put pressure on tendered hospital systems and emerging markets. Software is the third front: image storage and interpretation are increasingly software-led, and that layer is contested by specialists that sell no scanners at all. The tracer and nuclear business looks more insulated than the box business, which is the same conclusion the share data points to.
Durability: what would confirm or break the rating
The rating would strengthen if Pharmaceutical Diagnostics grew well beyond 14% of revenue at stable prices, if PET's share of myocardial perfusion procedures moved toward 25%, or if CT share held or rose while returns on total invested capital climbed toward the mid-teens as earnings grew against a fixed goodwill balance. It would weaken if CT share slipped below the mid-teens on Chinese tenders, if service pricing came under pressure, or if operating cash flow kept lagging net income beyond a single half-year.
Two things that look like protection are not. Imaging brand recognition does not stop Siemens Healthineers or Philips from bidding into the same budget, and a large balance sheet buys capacity to acquire rather than protection from competition. The advantage that survives scrutiny is narrower than the product range: an installed base that makes repeat purchasing easier, and a radiopharmacy and licensing position that takes years and capital to replicate. Whether that is enough to hold the Moderate rating depends on the mix between those two, and the mix is still moving.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Comparison and summaryHow GE HealthCare Technologies Inc. compares with its closest rivals, and our moat rating
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
Business, moat and key questions
Open company page